InvestorsHub Logo
Followers 58
Posts 10057
Boards Moderated 1
Alias Born 09/21/2016

Re: Tasso1 post# 360326

Saturday, 05/14/2022 7:57:01 AM

Saturday, May 14, 2022 7:57:01 AM

Post# of 458960
Tasso1

Patent Overview Anavex.

https://patents.justia.com/assignee/anavex-life-sciences-corp

Looks like Anavex is taking their science seriously - otherwise all this work would be wasted.
Maybe also gives an idea of ??why things are taken so long, if you constantly have to make sure you have the entire patent basis in place.



Agree. Makes one consider what might have been learned about the degree of difficulty (read confidence level) one must place in existing regulatory body trial -accuracy-reliability.

I read this new patent path initiative(s) as an indication that BIOPHARMA wants to fly and control it's OWN AIRPLANE. EXCELLENT.... We get more useful information about evolving treatment efficacy ...just excellent. IMO. Probably should have happened a long time ago. Three (FDA controlled) decades of CNS trial work and NO PROGRESS IS UNACCEPTABLE.

These CNS patent (how to) trial initiatives are very good news IMO. They drive the level of detail and control needed to make real-learning progress. IMO, this is the kind of change required when an organization begins to see and to deal with those things in their development-learning process that they , "Know they do not know" and which MUST BE FIXED. My guess would be they know there are critical control points in the knowledge generation process which must be managed at a much more granular level in order to best understand the science...IMO. It's complicated, but it explains WHY NOW...IMO.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News